Loading…

Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C

Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation o...

Full description

Saved in:
Bibliographic Details
Published in:Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2019-09, Vol.28 (9), p.1217-1222
Main Authors: Małyszczak, Krzysztof, Inglot, Małgorzata, Frydecka, Dorota, Hadryś, Tomasz, Pawłowski, Tomasz
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c329t-42233d9962597fba712d622217910024abe1a19ae45644fe3426cc7c0c81e6733
cites
container_end_page 1222
container_issue 9
container_start_page 1217
container_title Advances in clinical and experimental medicine : official organ Wroclaw Medical University
container_volume 28
creator Małyszczak, Krzysztof
Inglot, Małgorzata
Frydecka, Dorota
Hadryś, Tomasz
Pawłowski, Tomasz
description Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation of depressive symptoms and major depressive disorder (MDD) during hepatitis C treatment. A total of 99 patients receiving pegylated IFN-α and ribavirin for chronic C type hepatitis participated in the prospective cohort study. Symptoms of depression were assessed with the MontgomeryÅsberg Depression Rating Scale (MADRS) during treatment and 24 weeks after treatment. Neuroticism was measured with the Eysenck Personality Questionnaire - Revised (EPQ-R/N). Diagnosis of MDD was made using the Present State Examination (PSE-10) and DSM-IV-TR criteria. Factor analysis was used to detect factors adding up to total severity of depressive symptoms. Predictors of MDD were investigated using logistic regression analysis. Factor analysis returned 3 factors: 1st - MADRS scores at weeks 0-12, 2nd - MADRS and N scores before treatment, 3rd - MADRS at the 24th week of treatment and 24 weeks after treatment. The total severity of depressive symptoms consisted of 3 components: personality-related before treatment, IFN-α-related during treatment and dependent on the effect of treatment. Regression analysis showed that a history of psychiatric disorders (OR = 4.8) and MADRS scores before treatment (OR = 1.25) were predictors of MDD, as opposed to level of neuroticism. The severity of depressive symptoms and MDD during the hepatitis C treatment was related to general depressive vulnerability, not to psychological factors related to neuroticism.
doi_str_mv 10.17219/acem/104617
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2187027292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2187027292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-42233d9962597fba712d622217910024abe1a19ae45644fe3426cc7c0c81e6733</originalsourceid><addsrcrecordid>eNo9kD1PwzAURT2AaFW6MSOPDITaz25cj1BRqFTBAnPkOi-NURIbO0Xqv6cf0Ls86b6jOxxCbjh74Aq4nhiL7YQzmXN1QYZ8pnU2BZUPyDilL7aP1KCZvCIDwWacayaGpH1yvvEbZ01DTVfSkHa2PjfWt8F32PWJ-oqWGCKm5HxHXUeD6d3xE9Gi-3Hdhi4Xb5lpQm1oX2M0YUcrH2mNB7R3ic6vyWVlmoTjvzsin4vnj_lrtnp_Wc4fV5kVoPtMAghRap3DVKtqbRSHMgcArjRnDKRZIzdcG5TTXMoKhYTcWmWZnXHMlRAjcnfaDdF_bzH1ReuSxaYxHfptKoDPFAMFGvbo_Qm10acUsSpCdK2Ju4Kz4ui1OHgtTl73-O3f8nbdYnmG_42KX01odaM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2187027292</pqid></control><display><type>article</type><title>Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C</title><source>Directory of Open Access Journals</source><creator>Małyszczak, Krzysztof ; Inglot, Małgorzata ; Frydecka, Dorota ; Hadryś, Tomasz ; Pawłowski, Tomasz</creator><creatorcontrib>Małyszczak, Krzysztof ; Inglot, Małgorzata ; Frydecka, Dorota ; Hadryś, Tomasz ; Pawłowski, Tomasz</creatorcontrib><description>Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation of depressive symptoms and major depressive disorder (MDD) during hepatitis C treatment. A total of 99 patients receiving pegylated IFN-α and ribavirin for chronic C type hepatitis participated in the prospective cohort study. Symptoms of depression were assessed with the MontgomeryÅsberg Depression Rating Scale (MADRS) during treatment and 24 weeks after treatment. Neuroticism was measured with the Eysenck Personality Questionnaire - Revised (EPQ-R/N). Diagnosis of MDD was made using the Present State Examination (PSE-10) and DSM-IV-TR criteria. Factor analysis was used to detect factors adding up to total severity of depressive symptoms. Predictors of MDD were investigated using logistic regression analysis. Factor analysis returned 3 factors: 1st - MADRS scores at weeks 0-12, 2nd - MADRS and N scores before treatment, 3rd - MADRS at the 24th week of treatment and 24 weeks after treatment. The total severity of depressive symptoms consisted of 3 components: personality-related before treatment, IFN-α-related during treatment and dependent on the effect of treatment. Regression analysis showed that a history of psychiatric disorders (OR = 4.8) and MADRS scores before treatment (OR = 1.25) were predictors of MDD, as opposed to level of neuroticism. The severity of depressive symptoms and MDD during the hepatitis C treatment was related to general depressive vulnerability, not to psychological factors related to neuroticism.</description><identifier>ISSN: 1899-5276</identifier><identifier>DOI: 10.17219/acem/104617</identifier><identifier>PMID: 30811903</identifier><language>eng</language><publisher>Poland</publisher><ispartof>Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2019-09, Vol.28 (9), p.1217-1222</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-42233d9962597fba712d622217910024abe1a19ae45644fe3426cc7c0c81e6733</citedby><orcidid>0000-0002-3997-609X ; 0000-0001-8582-9958 ; 0000-0003-4120-7748 ; 0000-0001-6295-2742 ; 0000-0002-6173-7909</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30811903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Małyszczak, Krzysztof</creatorcontrib><creatorcontrib>Inglot, Małgorzata</creatorcontrib><creatorcontrib>Frydecka, Dorota</creatorcontrib><creatorcontrib>Hadryś, Tomasz</creatorcontrib><creatorcontrib>Pawłowski, Tomasz</creatorcontrib><title>Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C</title><title>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</title><addtitle>Adv Clin Exp Med</addtitle><description>Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation of depressive symptoms and major depressive disorder (MDD) during hepatitis C treatment. A total of 99 patients receiving pegylated IFN-α and ribavirin for chronic C type hepatitis participated in the prospective cohort study. Symptoms of depression were assessed with the MontgomeryÅsberg Depression Rating Scale (MADRS) during treatment and 24 weeks after treatment. Neuroticism was measured with the Eysenck Personality Questionnaire - Revised (EPQ-R/N). Diagnosis of MDD was made using the Present State Examination (PSE-10) and DSM-IV-TR criteria. Factor analysis was used to detect factors adding up to total severity of depressive symptoms. Predictors of MDD were investigated using logistic regression analysis. Factor analysis returned 3 factors: 1st - MADRS scores at weeks 0-12, 2nd - MADRS and N scores before treatment, 3rd - MADRS at the 24th week of treatment and 24 weeks after treatment. The total severity of depressive symptoms consisted of 3 components: personality-related before treatment, IFN-α-related during treatment and dependent on the effect of treatment. Regression analysis showed that a history of psychiatric disorders (OR = 4.8) and MADRS scores before treatment (OR = 1.25) were predictors of MDD, as opposed to level of neuroticism. The severity of depressive symptoms and MDD during the hepatitis C treatment was related to general depressive vulnerability, not to psychological factors related to neuroticism.</description><issn>1899-5276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kD1PwzAURT2AaFW6MSOPDITaz25cj1BRqFTBAnPkOi-NURIbO0Xqv6cf0Ls86b6jOxxCbjh74Aq4nhiL7YQzmXN1QYZ8pnU2BZUPyDilL7aP1KCZvCIDwWacayaGpH1yvvEbZ01DTVfSkHa2PjfWt8F32PWJ-oqWGCKm5HxHXUeD6d3xE9Gi-3Hdhi4Xb5lpQm1oX2M0YUcrH2mNB7R3ic6vyWVlmoTjvzsin4vnj_lrtnp_Wc4fV5kVoPtMAghRap3DVKtqbRSHMgcArjRnDKRZIzdcG5TTXMoKhYTcWmWZnXHMlRAjcnfaDdF_bzH1ReuSxaYxHfptKoDPFAMFGvbo_Qm10acUsSpCdK2Ju4Kz4ui1OHgtTl73-O3f8nbdYnmG_42KX01odaM</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Małyszczak, Krzysztof</creator><creator>Inglot, Małgorzata</creator><creator>Frydecka, Dorota</creator><creator>Hadryś, Tomasz</creator><creator>Pawłowski, Tomasz</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3997-609X</orcidid><orcidid>https://orcid.org/0000-0001-8582-9958</orcidid><orcidid>https://orcid.org/0000-0003-4120-7748</orcidid><orcidid>https://orcid.org/0000-0001-6295-2742</orcidid><orcidid>https://orcid.org/0000-0002-6173-7909</orcidid></search><sort><creationdate>20190901</creationdate><title>Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C</title><author>Małyszczak, Krzysztof ; Inglot, Małgorzata ; Frydecka, Dorota ; Hadryś, Tomasz ; Pawłowski, Tomasz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-42233d9962597fba712d622217910024abe1a19ae45644fe3426cc7c0c81e6733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Małyszczak, Krzysztof</creatorcontrib><creatorcontrib>Inglot, Małgorzata</creatorcontrib><creatorcontrib>Frydecka, Dorota</creatorcontrib><creatorcontrib>Hadryś, Tomasz</creatorcontrib><creatorcontrib>Pawłowski, Tomasz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Małyszczak, Krzysztof</au><au>Inglot, Małgorzata</au><au>Frydecka, Dorota</au><au>Hadryś, Tomasz</au><au>Pawłowski, Tomasz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C</atitle><jtitle>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</jtitle><addtitle>Adv Clin Exp Med</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>28</volume><issue>9</issue><spage>1217</spage><epage>1222</epage><pages>1217-1222</pages><issn>1899-5276</issn><abstract>Depressive symptoms are frequent side effects of interferon α therapy (IFN-α). Both biological and psychological processes may occur concomitantly during hepatitis C treatment. This study was carried out to determine the impact of biological (immune response) and psychological factors on formation of depressive symptoms and major depressive disorder (MDD) during hepatitis C treatment. A total of 99 patients receiving pegylated IFN-α and ribavirin for chronic C type hepatitis participated in the prospective cohort study. Symptoms of depression were assessed with the MontgomeryÅsberg Depression Rating Scale (MADRS) during treatment and 24 weeks after treatment. Neuroticism was measured with the Eysenck Personality Questionnaire - Revised (EPQ-R/N). Diagnosis of MDD was made using the Present State Examination (PSE-10) and DSM-IV-TR criteria. Factor analysis was used to detect factors adding up to total severity of depressive symptoms. Predictors of MDD were investigated using logistic regression analysis. Factor analysis returned 3 factors: 1st - MADRS scores at weeks 0-12, 2nd - MADRS and N scores before treatment, 3rd - MADRS at the 24th week of treatment and 24 weeks after treatment. The total severity of depressive symptoms consisted of 3 components: personality-related before treatment, IFN-α-related during treatment and dependent on the effect of treatment. Regression analysis showed that a history of psychiatric disorders (OR = 4.8) and MADRS scores before treatment (OR = 1.25) were predictors of MDD, as opposed to level of neuroticism. The severity of depressive symptoms and MDD during the hepatitis C treatment was related to general depressive vulnerability, not to psychological factors related to neuroticism.</abstract><cop>Poland</cop><pmid>30811903</pmid><doi>10.17219/acem/104617</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3997-609X</orcidid><orcidid>https://orcid.org/0000-0001-8582-9958</orcidid><orcidid>https://orcid.org/0000-0003-4120-7748</orcidid><orcidid>https://orcid.org/0000-0001-6295-2742</orcidid><orcidid>https://orcid.org/0000-0002-6173-7909</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1899-5276
ispartof Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2019-09, Vol.28 (9), p.1217-1222
issn 1899-5276
language eng
recordid cdi_proquest_miscellaneous_2187027292
source Directory of Open Access Journals
title Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A13%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biological%20and%20psychological%20components%20of%20depression%20in%20patients%20receiving%20IFN-alpha%20therapy%20for%20hepatitis%20C&rft.jtitle=Advances%20in%20clinical%20and%20experimental%20medicine%20:%20official%20organ%20Wroclaw%20Medical%20University&rft.au=Ma%C5%82yszczak,%20Krzysztof&rft.date=2019-09-01&rft.volume=28&rft.issue=9&rft.spage=1217&rft.epage=1222&rft.pages=1217-1222&rft.issn=1899-5276&rft_id=info:doi/10.17219/acem/104617&rft_dat=%3Cproquest_cross%3E2187027292%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c329t-42233d9962597fba712d622217910024abe1a19ae45644fe3426cc7c0c81e6733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2187027292&rft_id=info:pmid/30811903&rfr_iscdi=true